Charles Schwab
DAWN

Charles Schwab’s Day One Biopharmaceuticals DAWN Stock Holding History

Charles Schwab’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.2M Sell
617,561
-16,133
-3% -$227K ﹤0.01% 1969
2025
Q4 		$5.91M Buy
633,694
+23,630
+4% +$197K ﹤0.01% 2372
2025
Q3 		$4.3M Buy
610,064
+31,301
+5% +$215K ﹤0.01% 2504
2025
Q2 		$3.76M Buy
578,763
+50,615
+10% +$348K ﹤0.01% 2456
2025
Q1 		$4.19M Sell
528,148
-7,353
-1% -$79.2K ﹤0.01% 2342
2024
Q4 		$6.78M Buy
535,501
+28,053
+6% +$390K ﹤0.01% 2189
2024
Q3 		$7.07M Buy
507,448
+64,700
+15% +$923K ﹤0.01% 2193
2024
Q2 		$6.1M Sell
442,748
-14,904
-3% -$218K ﹤0.01% 2268
2024
Q1 		$7.56M Buy
457,652
+4,718
+1% +$70.6K ﹤0.01% 2125
2023
Q4 		$6.61M Buy
452,934
+5,796
+1% +$70.3K ﹤0.01% 2196
2023
Q3 		$5.49M Buy
447,138
+125,050
+39% +$1.63M ﹤0.01% 2210
2023
Q2 		$3.85M Buy
322,088
+119,421
+59% +$1.56M ﹤0.01% 2338
2023
Q1 		$2.71M Sell
202,667
-1,238
-0.6% -$24.2K ﹤0.01% 2441
2022
Q4 		$4.39M Buy
203,905
+4,953
+2% +$102K ﹤0.01% 2284
2022
Q3 		$3.99M Buy
198,952
+45,909
+30% +$976K ﹤0.01% 2339
2022
Q2 		$2.74M Buy
153,043
+49,009
+47% +$506K ﹤0.01% 2461
2022
Q1 		$1.03M Buy
104,034
+27,866
+37% +$368K ﹤0.01% 2836
2021
Q4 		$1.28M Buy
76,168
+942
+1% +$19.4K ﹤0.01% 2821
2021
Q3 		$1.79M Buy
+75,226
New +$1.8M ﹤0.01% 2724

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Charles Schwab's DAWN Position: Q1 2026 in Review

Charles Schwab reduced its Day One Biopharmaceuticals (DAWN) stake by 2.5% in Q1 2026, selling an estimated $227K and leaving 617,561 shares worth $13.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1969.

Charles Schwab first reported a position in DAWN in Q3 2021 and has held it in 19 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Charles Schwab held 617,561 shares of Day One Biopharmaceuticals worth $13.2M as of Q1 2026.
  • Charles Schwab sold 16,133 Day One Biopharmaceuticals shares in Q1 2026, an estimated $227K.
  • Day One Biopharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #1969 holding.
  • Charles Schwab first reported a position in Day One Biopharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.